Cydan Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Cydan General Information

Description

Operator of an orphan drug accelerator intended to create therapies that improve the lives of patients living with rare genetic diseases. The company accelerates therapies through clinical, regulatory, and commercial development for treating patients with rare diseases, with approved treatments, enabling patients and families with rare diseases to be treated in a salutary way and helping them recover soon.

Contact Information

Website
www.cydanco.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 700 Technology Square
  • 3rd Floor
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Corporate Office
  • 700 Technology Square
  • 3rd Floor
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cydan Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 31-Dec-2021 Completed Out of Business
2. Early Stage VC 17-Oct-2017 Completed Generating Revenue
1. Early Stage VC 01-Oct-2013 $26M $26M Completed Startup
To view Cydan’s complete valuation and funding history, request access »

Cydan Patents

Cydan Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210338782-A1 Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof Inactive 04-Oct-2019
US-20200157108-A1 Methods of making and using pde9 inhibitors Active 26-May-2017
US-20230183244-A1 Methods of making and using pde9 inhibitors Active 26-May-2017
US-11999741-B2 Process for the synthesis of 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one Active 26-May-2017
US-20250019381-A1 Process for the synthesis of 6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one Inactive 26-May-2017 C07D487/04
To view Cydan’s complete patent history, request access »

Cydan Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cydan Investments (4)

Cydan’s most recent deal was a Early Stage VC with Tiburio Therapeutics for . The deal was made on 03-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tiburio Therapeutics 03-Jan-2019 Early Stage VC Biotechnology
Hyasynth 13-Jul-2016 Accelerator/Incubator Other Pharmaceuticals and Biotechnology
HIVE Biosystems 24-Jun-2015 Accelerator/Incubator Discovery Tools (Healthcare)
Vtesse Accelerator/Incubator Drug Discovery
To view Cydan’s complete investments history, request access »

Cydan FAQs

  • When was Cydan founded?

    Cydan was founded in 2013.

  • Where is Cydan headquartered?

    Cydan is headquartered in Cambridge, MA.

  • What is the size of Cydan?

    Cydan has 6 total employees.

  • What industry is Cydan in?

    Cydan’s primary industry is Drug Discovery.

  • Is Cydan a private or public company?

    Cydan is a Private company.

  • What is Cydan’s current revenue?

    The current revenue for Cydan is .

  • How much funding has Cydan raised over time?

    Cydan has raised $60M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process